Mulnitorsen

N/A

Report date: 2022/11/13 11:45:00
NME

Base Information

Drug NameMulnitorsen
Drug Alias NameAntisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA) (Andes Biotechnologies)Andes-1537
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApoptosis stimulantsRNA interference
TargetsRibonucleic Acid
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesChile
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAndes Biotechnologies
China Registration ClassN/A

Develop Information

Active CompaniesAndes Biotechnologies
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsPancreatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A